Blar i Bergen Open Research Archive på forfatter "Chalabianloo, Fatemeh"
-
Attention-deficit/hyperactivity disorder (ADHD) symptoms and their relation to diagnosed ADHD, sociodemographic characteristics, and substance use among patients receiving opioid agonist therapy: a Norwegian cohort study
Vold, Jørn Henrik; Halmøy, Anne; Chalabianloo, Fatemeh; Pierron, Marianne Cook; Løberg, Else-Marie; Johansson, Kjell Arne; Fadnes, Lars T. (Journal article; Peer reviewed, 2023)Background Attention-deficit/hyperactivity disorder (ADHD) symptoms may challenge sufficient treatment of substance use and mental disorders. The literature on the extent of such symptoms among patients receiving opioid ... -
Changes in substance use during outpatient treatment for substance use disorders: a prospective Norwegian cohort study from 2016 to 2020
Vold, Jørn Henrik; Chalabianloo, Fatemeh; Aas, Christer Frode; Løberg, Else-Marie; Johansson, Kjell Arne; Fadnes, Lars T. (Journal article; Peer reviewed, 2021)Background Continuous use of amphetamines, alcohol, benzodiazepines, cannabis, cocaine, or opioids contributes to health impairments, increased morbidity, and overdose deaths among patients with substance use disorders ... -
Dispensation of attention deficit hyperactivity disorder (ADHD) medications in patients receiving opioid agonist therapy; A national prospective cohort study in Norway from 2015 to 2017
Vold, Jørn Henrik; Aas, Christer Frode; Skurtveit, Svetlana; Odsbu, Ingvild; Chalabianloo, Fatemeh; Halmøy, Anne; Johansson, Kjell Arne; Fadnes, Lars T. (Journal article; Peer reviewed, 2020)Background It is estimated that up to a third of patients on opioid agonist therapy (OAT) have attention deficit hyperactivity disorder (ADHD). Treatment by ADHD medication, including a centrally acting stimulant (CAS) ... -
Dispensations of benzodiazepines, zhypnotics, and gabapentinoids to patients receiving opioid agonist therapy; a prospective cohort study in Norway from 2013 to 2017
Vold, Jørn Henrik; Skurtveit, Svetlana; Aas, Christer Frode; Chalabianloo, Fatemeh; Kloster, Pia Synnøve; Johansson, Kjell Arne; Fadnes, Lars T. (Journal article; Peer reviewed, 2020)Background Dispensations of benzodiazepines, z-hypnotics, and gabapentinoids to patients on opioid agonist therapy (OAT) are common and have pros and cons. The objectives of the current study are to define the dispensation ... -
Effect of integrated hepatitis C virus treatment on psychological distress in people with substance use disorders
Aas, Christer Frode; Vold, Jørn Henrik; Chalabianloo, Fatemeh; Løberg, Else-Marie; Lim, Aaron G.; Vickerman, Peter; Johansson, Kjell Arne; Fadnes, Lars T. (Journal article; Peer reviewed, 2024)People with substance use disorders (SUD) have a high prevalence of chronic hepatitis C virus (HCV) infection and mental health disorders. We aimed to assess the impact of integrated HCV treatment on psychological distress ... -
Effectiveness and Safety of Low-Threshold Opioid-Agonist Treatment in Hard-To-Reach Populations with Opioid Dependence
Chalabianloo, Fatemeh; Ohldieck, Christian; Haaland, Øystein Ariansen; Fadnes, Lars T.; Johansson, Kjell Arne (Journal article; Peer reviewed, 2021)Objectives: Opioid-use disorder is related to premature death worldwide. Opioid-agonist treatment (OAT) is an effective treatment for opioid dependence. OAT delivery platforms may influence treatment access and outcomes, ... -
The efficacy of integrated hepatitis C virus treatment in relieving fatigue in people who inject drugs: a randomized controlled trial
Vold, Jørn Henrik; Chalabianloo, Fatemeh; Løberg, Else-Marie; Aas, Christer Frode; Lim, Aaron G.; Vickerman, Peter; Johansson, Kjell Arne; Fadnes, Lars T. (Journal article; Peer reviewed, 2023)Background Most people who inject drugs (PWIDs) suffer from severe fatigue, and chronic hepatitis C virus (HCV) infection may play a role in this. However, there is scarce evidence about interventions that alleviate ... -
Impact of clinical and sociodemographic factors on fatigue among patients with substance use disorder: a cohort study from Norway for the period 2016–2020
Vold, Jørn Henrik; Gjestad, Rolf; Aas, Christer Frode; Chalabianloo, Fatemeh; Skurtveit, Svetlana; Løberg, Else-Marie; Johansson, Kjell Arne; Fadnes, Lars T. (Journal article; Peer reviewed, 2020)Background The impact of clinical and sociodemographic factors on fatigue remains unknown among patients with substance use disorders (SUD). This study aims to evaluate fatigue among patients with SUD using a nine-item ... -
Impact of liver fibrosis and clinical characteristics on dose-adjusted serum methadone concentrations
Chalabianloo, Fatemeh; Høiseth, Gudrun; Vold, Jørn Henrik; Johansson, Kjell Arne; Kringen, Marianne K.; Dalgard, Olav; Ohldieck, Christian; Druckrey-Fiskaaen, Karl Trygve; Aas, Christer Frode; Løberg, Else-Marie; Bramness, Jørgen Gustav; Fadnes, Lars T. (Journal article; Peer reviewed, 2023)Background: There is limited knowledge on the causes of large variations in serum methadone concentrations and dose requirements. Objectives: We investigated the impact of the degree of liver fibrosis on dose-adjusted ... -
Integrated care of severe infectious diseases to people with substance use disorders; a systematic review
Vold, Jørn Henrik; Aas, Christer Frode; Leiva, Rafael Alexander Mo; Vickerman, Peter; Chalabianloo, Fatemeh; Løberg, Else-Marie; Johansson, Kjell Arne; Fadnes, Lars T. (Peer reviewed; Journal article, 2019)Background: Various integrated care models have been used to improve treatment completion of medications for chronic hepatitis B virus (HBV), chronic hepatitis C virus (HCV), Mycobacterium tuberculosis (TB), and Human ... -
Integrated treatment of hepatitis C virus infection among people who inject drugs: A multicenter randomized controlled trial (INTRO-HCV)
Fadnes, Lars T.; Aas, Christer Frode; Vold, Jørn Henrik; Leiva, Rafael Alexander Mo; Ohldieck, Christian; Chalabianloo, Fatemeh; Skurtveit, Svetlana Ondrasova; Lygren, Ole Jørgen; Dalgard, Olav; Vickerman, Peter; Midgard, Håvard; Løberg, Else-Marie; Johansson, Kjell Arne (Journal article; Peer reviewed, 2021)Background The standard pathways of testing and treatment for hepatitis C virus (HCV) infection in tertiary healthcare are not easily accessed by people who inject drugs (PWID). The aim of this study was to evaluate the ... -
Integrated treatment of hepatitis C virus infection among people who inject drugs: study protocol for a randomised controlled trial (INTRO-HCV)
Fadnes, Lars T.; Aas, Christer Frode; Vold, Jørn Henrik; Ohldieck, Christian; Leiva, Rafael Alexander Mo; Chalabianloo, Fatemeh; Skurtveit, Svetlana; Lygren, Ole Jørgen; Dalgard, Olav; Vickerman, Peter; Midgard, Håvard; Løberg, Else-Marie; Johansson, Kjell Arne (Peer reviewed; Journal article, 2019-11-08)Background: A large proportion of people who inject drugs (PWID) living with hepatitis C virus (HCV) infection have not been treated. It is unknown whether inclusion of HCV diagnostics and treatment into integrated substance ... -
Methadone pharmacokinetics in opioid agonist treatment: Influencing factors and clinical implications
Chalabianloo, Fatemeh; Fadnes, Lars T.; Johansson, Kjell Arne; Høiseth, Gudrun; Vold, Jørn Henrik; Kringen, Marianne K.; Spigset, Olav; Bramness, Jørgen Gustav (Journal article; Peer reviewed, 2024)Background A considerable inter-individual variability has been reported in the relationship between methadone doses applied and serum concentrations achieved in methadone maintenance treatment. However, the underlying ... -
On the path towards universal coverage of hepatitis C treatment among people receiving opioid agonist therapy (OAT) in Norway: A prospective cohort study from 2013 to 2017
Aas, Christer Frode; Vold, Jørn Henrik; Skurtveit, Svetlana; Odsbu, Ingvild; Chalabianloo, Fatemeh; Økland, Jan-Magnus; Leiva, Rafael Alexander Mo; Vickerman, Peter; Johansson, Kjell Arne; Fadnes, Lars T. (Journal article; Peer reviewed, 2020)Objectives We aimed to calculate cumulative hepatitis C virus (HCV) treatment coverage among individuals enrolled in opioid agonist therapy (OAT) in Norway between 2013 and 2017 and to document the treatment transition to ... -
Potentially addictive drugs dispensing to patients receiving opioid agonist therapy: a register-based prospective cohort study in Norway and Sweden from 2015 to 2017
Vold, Jørn Henrik; Aas, Christer Frode; Skurtveit, Svetlana; Odsbu, Ingvild; Chalabianloo, Fatemeh; Reutfors, Johan; Halmøy, Anne; Johansson, Kjell Arne; Fadnes, Lars T. (Journal article; Peer reviewed, 2020)Objectives: To compare the use of benzodiazepines, z-hypnotics, gabapentinoids, opioids and centrally acting stimulants (CAS) among patients who had received opioid agonist therapy (OAT) in Norway and Sweden during the ... -
Steady-state methadone pharmacokinetics in opioid agonist treatment: Influencing factors and clinical outcomes
Chalabianloo, Fatemeh (Doctoral thesis, 2022-12-14)Bakgrunn: Metadonsubstitusjon er anbefalt for behandling av opioidavhengighet. En betydelig inter-individuell variasjon i metadons daglige doser og oppnådde serumkonsentrasjoner er rapportert. Mulige underliggende årsaker ... -
Subjective symptoms and serum methadone concentrations: what should guide dose adjustments in methadone maintenance treatment? A naturalistic cohort study from Norway
Chalabianloo, Fatemeh; Fadnes, Lars T.; Høiseth, Gudrun; Ohldieck, Christian; Vold, Jørn Henrik; Aas, Christer Frode; Løberg, Else-Marie; Johansson, Kjell Arne; Bramness, Jørgen Gustav (Journal article; Peer reviewed, 2021)Background: There is little evidence-based guidance on how to optimize methadone dosages among patients with opioid addiction undergoing methadone maintenance treatment (MMT). This study aims to investigate whether ... -
Universal Health Coverage of Opioid Agonist Treatment in Norway: An Equity-Adjusted Economic Evaluation
Chaudhary, Prayash; Fadnes, Lars T.; Fosse, Steinar; Chalabianloo, Fatemeh; Johansson, Kjell Arne (Journal article; Peer reviewed, 2024)Background Detailed information on the efficiency of health services targeting opioid use disorder (OUD) and treatment with opioid agonist treatment (OAT) is sparse. Many countries, including Norway, are still falling ... -
Uptake and predictors of direct-acting antiviral treatment for hepatitis C among people receiving opioid agonist therapy in Sweden and Norway: a drug utilization study from 2014 to 2017
Aas, Christer Frode; Vold, Jørn Henrik; Skurtveit, Svetlana; Odsbu, Ingvild; Chalabianloo, Fatemeh; Lim, Aaron G.; Johansson, Kjell Arne; Fadnes, Lars T. (Journal article; Peer reviewed, 2020)Background Treatment with direct-acting antiviral agents (DAAs) offers an opportunity to eliminate hepatitis C virus (HCV) endemic among people who inject drugs (PWID) and people enrolled in opioid agonist therapy (OAT) ...